"It's early days," says Antonio Pagliuca, professor of stem cell transplantation at King's.
Daley, director of the stem cell transplantation program at Children's Hospital Boston.
Prof Chris Hawkey, a gastroenterologist at Nottingham University, is leading the Autologous Stem Cell Transplantation in Crohn's Disease (Astic) trial.
Professor Chris Hawkey, a gastroenterologist at Nottingham University, is leading the Autologous Stem Cell Transplantation in Crohn's Disease (Astic) trial.
Dr. Keith M. Sullivan, a professor of medicine who specializes in stem cell transplantation at the Duke University Medical Center, sees other developments on the horizon.
The stem cell transplantation is used to kill off the patient's old bone marrow that produces the harmful cells which cause the Crohn's and generate new healthy cells.
"I'm hopeful that half or more of the patients who undergo stem cell transplantation may either be cured or have a long-term remission," said Hawkey.
"It's not a business," said Robert Baitty, the director of the blood stem cell transplantation program at the Health Resources and Services Administration.
The stem cell transplantation is used to kill off the patient's old bone marrow, which produces the harmful cells that cause the Crohn's, and generate new cells.
"I'm hopeful that half or more of the partients that undergo stem cell transplantation may either be cured or have a long-term remission," Hawkey said.
stem cell transplantation.
